Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases   3 Products   28 Trials   310 News 


«123456789»
  • ||||||||||  conbercept (KH902) / Chengdu Kanghong
    Retrospective data, Journal:  Microvascular changes after conbercept therapy in central retinal vein occlusion analyzed by optical coherence tomography angiography. (Pubmed Central) -  May 28, 2019   
    Neural recovery occurred after the resolution of edema during conbercept treatment, due to the decreases in GCL and IPL associating with gains in vision and improved microperimetry. OCTA enables the non-invasive, layer-specific and quantitative assessment of microvascular changes both before and after treatment, and can therefore be used as a valuable imaging tool for the evaluation of the follow-up in CRVO patients.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion, Trial completion date:  Intravitreal Conbercept After Vitrectomy (clinicaltrials.gov) -  Apr 29, 2019   
    P1,  N=50, Completed, 
    The regression of neovascularization reaches a plateau 3 days after IVC. Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Feb 2019
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    Trial primary completion date, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Apr 23, 2019   
    P4,  N=80, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> Feb 2019 Trial primary completion date: Jan 2019 --> May 2019
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Treatment of retinopathy of incontinentia pigmenti by anti-vascular endothelial growth factor (Pubmed Central) -  Apr 20, 2019   
    The efficacy of anti-vascular endothelial growth factor in the treatment of retinopathy of incontinentia pigmenti was prelininarily confimed.However,the optimal use timing,dosage,local and systemic safety issues were needed to be further studied. (Chin J Ophthalmol, 2019, 55:294-301).
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, conbercept (KH902) / Chengdu Kanghong
    Clinical, Review, Journal:  The efficacy and safety of aflibercept and conbercept in diabetic macular edema. (Pubmed Central) -  Mar 25, 2019   
    Advantages have been shown for aflibercept and conbercept, the two recombinant decoy receptors that can bind VEGF with high specificity and affinity, in DME treatment in clinical trials conducted both worldwide and in People's Republic of China. This review introduces the structural characteristics and molecular mechanisms of action of these two anti-VEGF drugs, and summarizes the clinical trials evaluating their efficacy and safety, with the hope to provide clues for designing optimal and personalized therapeutic regimens for DME patients.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment open, Trial initiation date:  Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) (clinicaltrials.gov) -  Mar 5, 2019   
    P3,  N=1140, Recruiting, 
    This review introduces the structural characteristics and molecular mechanisms of action of these two anti-VEGF drugs, and summarizes the clinical trials evaluating their efficacy and safety, with the hope to provide clues for designing optimal and personalized therapeutic regimens for DME patients. Not yet recruiting --> Recruiting | Initiation date: Sep 2018 --> Dec 2018
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Biotech
    New trial:  PRP vs PRP+IVC for Severe nPDR (clinicaltrials.gov) -  Mar 4, 2019   
    P=N/A,  N=40, Recruiting, 
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    Trial primary completion date, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Jan 25, 2019   
    P4,  N=80, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Sep 2018 --> Dec 2018 Trial primary completion date: Jan 2018 --> Jan 2019
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Trial completion date, Trial primary completion date:  CRVO: Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (clinicaltrials.gov) -  Sep 21, 2018   
    P3,  N=237, Recruiting, 
    Trial completion date: Jul 2018 --> Dec 2020 | Trial primary completion date: Jan 2018 --> Dec 2019 Trial completion date: Oct 2018 --> Dec 2020 | Trial primary completion date: Apr 2018 --> Dec 2019
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    New P1 trial:  Intravitreal Conbercept After Vitrectomy (clinicaltrials.gov) -  Feb 8, 2018   
    P1,  N=50, Active, not recruiting, 
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    Enrollment open, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Jan 4, 2017   
    P4,  N=80, Recruiting, 
    Active, not recruiting --> Enrolling by invitation | Initiation date: Sep 2016 --> Oct 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    Trial initiation date, Trial primary completion date, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Dec 15, 2016   
    P4,  N=80, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Jan 2018
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion, Head-to-Head:  RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) -  Aug 2, 2016   
    P4,  N=12, Completed, 
    Initiation date: Jul 2016 --> Jan 2017 | Trial primary completion date: Jul 2017 --> Jan 2018 Recruiting --> Completed
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma, Visudyne (verteporfin) / Novartis
    New P4 trial, Combination therapy:  Initial Versus Delayed PDT Combination With Conbercept in PCV (clinicaltrials.gov) -  Jul 1, 2016   
    P4,  N=80, Not yet recruiting, 
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment open, Head-to-Head:  RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) -  May 5, 2016   
    P4,  N=12, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting